Bone Marrow Stromal Cells Derived MCP-1 Reverses the Inhibitory Effects of Multiple Myeloma Cells on Osteoclastogenesis by Upregulating the RANK Expression

• Zhiqiang Liu ,

  Contributed equally to this work with: Zhiqiang Liu, Jingda Xu

  Affiliation Department of Lymphoma and Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Jingda Xu ,

  Contributed equally to this work with: Zhiqiang Liu, Jingda Xu

  Affiliation Department of Lymphoma and Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Haiyan Li,

  Affiliation Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America

  ⨯
• Yuhuan Zheng,

  Affiliation Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America

  ⨯
• Jin He,

  Affiliation Department of Lymphoma and Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Huan Liu,

  Affiliation Department of Lymphoma and Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Yuping Zhong,

  Affiliation Department of Lymphoma and Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Yong Lu,

  Affiliation Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America

  ⨯
• Bangxing Hong,

  Affiliation Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America

  ⨯
• Mingjun Zhang,

  Affiliation Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America

  ⨯
• Pei Lin,

  Affiliation Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Juan Du,

  Affiliation Department of Hematology, The Myeloma & Lymphoma Center, Changzheng Hospital, The Second Military Medical University, Shanghai, China

  ⨯
• Jian Hou,

  Affiliation Department of Hematology, The Myeloma & Lymphoma Center, Changzheng Hospital, The Second Military Medical University, Shanghai, China

  ⨯
• Jianfei Qian,

  Affiliation Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America

  ⨯
• Larry W. Kwak,

  Affiliation Department of Lymphoma and Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Qing Yi,

  Affiliation Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America

  ⨯
•  [ ... ],
• Jing Yang

  * E-mail: jiyang@mdanderson.org

  Affiliation Department of Lymphoma and Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• [ view all ]
• [ view less ]